Updated on June 12, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
If you are an adult with current symptoms or a history of depression, you may be eligible for this research study. Symptoms may include feeling sad, worthless or guilty, having trouble eating or sleeping, having no motivation, or having difficulty concentrating. If you qualify, all study-related care will be provided at no cost, and you will be compensated for time and travel. There are no overnight stays required.
The research site is in Memphis, Tenn.
Migraine and Cluster Headaches
This study will evaluate the effectiveness and safety of an investigational medication to treat acute migraine headaches. Qualified participants will receive either one or two doses of the investigational medication, Zomig 5mg, or a placebo (an inactive substance). Volunteers 18 or older with a history of migraines -- with or without aura -- for greater than one year may be eligible.
The research site is in Palm Beach Gardens, Fla.
Copyright 2007 Thomson CenterWatch. All rights reserved.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.